Evidence map›Paper›PMID 36660641›Full record

ArticleAnnals of translational medicine2022

To explore the active constituents of

Bo-Jie Zhu, Guan-Ye Nai, Tian-Xiao Pan, Zhou-Fei Ma, Zi-Dong Huang, Zong-Ze Shi, Ying-Hua Pang, Na Li, Jia-Xi Lin, Gui-Mei Ling

Open access · diamondAbstract read
In one paragraph

Article in Annals of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Frontiers in pharmacology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Bo-Jie Zhu *The Department of Chinese Medicine, The People's Hospital of Baise, Baise, China.
Guan-Ye Nai *Department of Hematology, The Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, China.
Tian-Xiao PanThe Department of Chinese Medicine, The People's Hospital of Baise, Baise, China.
Zhou-Fei MaSchool of Dentistry, The Youjiang Medical University for Nationalities, Baise, China.
Zi-Dong HuangThe Department of Chinese Medicine, The People's Hospital of Baise, Baise, China.
Zong-Ze ShiThe Department of Chinese Medicine, The People's Hospital of Baise, Baise, China.
Ying-Hua PangThe Department of Chinese Medicine, The People's Hospital of Baise, Baise, China.
Na LiThe Department of Chinese Medicine, The People's Hospital of Baise, Baise, China.
Jia-Xi LinThe Department of Chinese Medicine, The People's Hospital of Baise, Baise, China.
Gui-Mei LingThe Department of Chinese Medicine, The People's Hospital of Baise, Baise, China.
Baise University · CNAffiliated Hospital of Youjiang Medical University for Nationalities · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: There is a lack of effective drugs for the treatment of coronary heart disease (CHD). Methods: The targets and active ingredients of SL were screened using the Traditional Chinese Medicine Systems Pharmacology (TCMSP) database, and CHD-related targets were obtained by searching GeneCards and DisGeNet databases. The intersection of LS active ingredient targets and CHD targets was used to construct a "drug-ingredient-disease-target" network using the Cytoscape software. The STRING database was used to construct a protein-protein interaction (PPI) network, and Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were performed. Key targets and core active ingredients were selected and molecular docking was performed using the AutoDock software. Results: According to the predicted results, a total of 134 corresponding target genes for LS, 12 active components, 1,704 CHD-related targets, and 52 intersecting targets were obtained. GO function and KEGG pathway analysis showed that the key targets were involved with signal transducer and activator of transcription 3 ( Conclusions: SL may act on targets such as

Indexed as

coronary heart disease (CHD)molecular dockingnetwork pharmacologySedum aizoon L (SL)

Identifiers

PMID36660641
PMCPMC9843314
OpenAlexW4313409885

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.